Therapure, LFB in Development Services Contract

Therapure BioPharma, Inc. has been selected by LFB Biotechnologies, a subsidiary of LFB SA, for the development of a manufacturing method for a plasma therapeutic protein. Therapure will develop a manufacturing process for the large-scale production of a biologic for clinical trials. R&D teams from both companies will manage the project. The potential treatment is for a serious illness that currently has limited treatment options, according to a joint statement.

“We are pleased that LFB Biotechnologies, a major European player in the therapeutic protein field, has selected Therapure Biopharma for this important work,” said Thomas Wellner, president and chief executive officer of Therapure BioPharma. “Our development team has extensive knowledge in the area of plasma proteins purification and manufacturing methods and we have already achieved some key milestones in this project.”

“We have a strong expertise in the development and manufacture of plasma-derived medicinal products and an important R&D portfolio.  We have chosen to identify partners with complementary knowledge and the skills to help us to advance some of our products,” said Bernard Pelletier, strategic development program director, LFB Biotechnologies. “We have recognized the strong technical capabilities of Therapure Biopharma in this area and we are pleased with the progress of the project to date.”